|
| Study | Country | Type of study | Audiological tests conducted | Patient population | Number of patients who developed ototoxicity |
|
| Malgonde et al. [47] | India | Prospective | Pure tone audiometry (frequencies not specified) and short increment sensitivity index test | 34 patients with head and neck cancers receiving cisplatin containing chemotherapy and concomitant radiation therapy | 34 (100%) |
|
| Whitehorn et al. [48] | South Africa | Retrospective cross-sectional | Air (0.25–8 kHz) and bone conduction pure tone audiometry | 107 patients receiving cisplatin containing chemotherapy, irrespective of the type of the cancer | 59 (55.1%) |
|
| Nitz et al. [49] | Germany | Prospective longitudinal trinational population-based | Air (0.125–8 kHz) and bone conduction pure tone audiometry | 1 patient with soft-tissue sarcoma and 16 with osteosarcoma, receiving cisplatin and/or carboplatin containing chemotherapy | 6 (35.3%) |
|
| Arora et al. [8] | India | Prospective, randomized, observational | Pure tone air (0.25–16 kHz) and bone conduction audiometry
Results are reflective of frequencies 4 to 16 kHz. | 57 patients receiving cisplatin containing chemotherapy: | — |
| 10 patients (low dose group, carcinoma of the larynx) | 6 (60%) |
| 35 patients (middle dose group, head and neck cancers, carcinoma of the cervix) | 35 (100%) |
| 12 patients (high dose group, carcinoma of the lung and carcinoma of the testis) | 12 (100%) |
|
| Dell’Aringa et al. [50] | Brazil | Case series | Tympanometry, acoustic reflex threshold testing, distortion product otoacoustic emissions (DPOAEs), air (0.25–8 kHz) and bone conduction pure tone audiometry, speech audiometry | 17 patients with extracranial head and neck cancers receiving cisplatin containing chemotherapy and concomitant radiation therapy | 12 (70.5%), left ears; 11 (64.7%), right ears |
|
| Schultz et al. [51] | Brazil | Prospective | Full audiometric evaluations, with only air (0.25–8 kHz) and bone conduction pure tone audiometry thresholds computed | 31 patients receiving cisplatin containing chemotherapy, irrespective of the type of cancer | 12 (38%), NCI criteria; 19 (65%), Brock et al.’s criteria; 17 (54%), ASHA criteria; 9 (29%), David and Silverman’s criteria |
|
| Zuur et al. [52] | The Netherlands | Prospective | Air (0.125–16 kHz) and bone conduction pure tone audiometry | 60 patients with locally advanced head and neck cancer, receiving cisplatin containing chemotherapy and concomitant radiation therapy | 19 (31%), up to 8 kHz; 28 (47%), up to 16 kHz |
|
| Dutta et al. [36] | India | Prospective | Pure tone audiometry (frequencies not specified) | 60 patients receiving cisplatin containing chemotherapy, type of cancer not indicated | 9 (15%) |
| 51, low dose group | 6 (12%) |
| 9, high dose group | 3 (33%) |
|
| Strumberg et al. [53] | Germany | Retrospective | Pure tone air (0.125–12 kHz) and bone conduction audiometry, transient evoked otoacoustic emissions test (TEOAE) | 32 patients with testicular cancer receiving cisplatin containing chemotherapy | 21 (70%) |
|
| Nagy et al. [54] | USA | Retrospective | Tympanometry, air (0.25–8 KHz) conduction pure tone audiometry | 53 patients with oesophageal, lung, or head and neck cancer receiving cisplatin containing chemotherapy and concomitant radiation therapy (only for head and neck cancer) | 19 (36%) |
|
| Bokemeyer et al. [35] | Germany | Retrospective | Pure tone air (0.5–8 kHz) and bone audiometry | 86 patients with testicular cancer receiving cisplatin containing chemotherapy | 57 (66%) |
|
| Waters et al. [32] | Canada | Retrospective | Pure tone air (0.25–8 kHz) and bone conduction audiometry, immittance audiometry, and speech audiometry | 60 patients with advanced ovarian carcinomas receiving cisplatin containing chemotherapy | |
| 39, low dose, short treatment (25 from LDE group and 14 new cases after treatment modification) | 6 (15%) |
| 8, low dose, blocks | 0 (0%) |
| 25, low dose, extended treatment | 9 (36%) |
| 13, high dose, short treatment | 12 (92%) |
|
